Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 12/20 | 0.37 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1605420 | 1.00 | IDH1 (0.40) | IDH1PDE2ATEAD1CNR1CNR2 | |
| SCHEMBL1605776 | 0.87 | IDH1 (0.39) | IDH1 | |
| SCHEMBL14429434 | 0.85 | IDH1 (0.43) | IDH1CNR1CNR2 | |
| SCHEMBL1606410 | 0.85 | MAPKAPK2 (0.41) | IDH1 | |
| SCHEMBL1606487 | 0.85 | MAPKAPK2 (0.41) | IDH1 | |
| SCHEMBL14429777 | 0.84 | IDH1 (0.36) | IDH1GPR139TRPV1 | |
| SCHEMBL14429779 | 0.84 | IDH1 (0.36) | IDH1GPR139TRPV1 | |
| SCHEMBL10249378 | 0.84 | IDH1 (0.36) | IDH1GPR139TRPV1 | |
| SCHEMBL10248170 | 0.84 | IDH1 (0.36) | IDH1GPR139TRPV1 | |
| SCHEMBL10249354 | 0.84 | IDH1 (0.36) | IDH1GPR139TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541592-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | IDH1 191/4885PDE2A 1210/4885TEAD1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.